Brigatinib

Brigatinib is a prescription medication used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) and is caused by certain types of abnormal ALK genes. Brigatinib is a type of targeted therapy called an ALK inhibitor. It works by blocking the action of certain proteins that help cancer cells grow and spread in the body.

Brigatinib, sold under the brand name Alunbrig, is a prescription medication used to treat specific types of non-small cell lung cancer (NSCLC) in adults. Here's a breakdown of its key points:

What it treats:

• Brigatinib is approved for the treatment of NSCLC with a specific genetic alteration. This alteration involves a mutation in a gene called ALK (anaplastic lymphoma kinase). Not all cases of NSCLC have this mutation, and testing is necessary to determine if brigatinib is the appropriate treatment option.
• It is typically used for patients whose cancer has progressed (worsened) after treatment with other medications, such as crizotinib (Xalkori).

How it works:

• Brigatinib belongs to a class of medications called ALK tyrosine kinase inhibitors (TKIs). These drugs work by targeting and blocking the abnormal activity of the ALK protein, which plays a role in the growth and spread of cancer cells.
• By inhibiting ALK, brigatinib can help to slow down the growth of cancer cells and potentially shrink tumors.

How it's administered:

• Brigatinib is taken orally, typically as a capsule, once a day with or without food.

Important considerations:

• Brigatinib can cause various side effects, including fatigue, nausea, diarrhea, cough, pulmonary complications (lung problems), and vision problems.
• It is important to disclose all medical conditions and medications you are taking to your doctor before starting treatment with brigatinib, as there can be potential interactions with other drugs.
• Pregnancy and breastfeeding are not recommended while using brigatinib due to the potential for harm to the developing fetus or newborn baby.